Genetics and epigenetics of primary biliary cirrhosis

Seminars in Liver Disease

Volumn 34, Issue 3, 2014, Pages 255-264

  Bianchi, Ilaria ^a   Carbone, Marco ^b,c   Lleo, Ana ^a   Invernizzi, Pietro ^a,d  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

genome wide association study; immune related pathways; novel drugs; primary biliary cirrhosis; sex chromosomes

Indexed keywords

I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 23; PHOSPHATIDYLINOSITOL; TUMOR NECROSIS FACTOR ALPHA; GENETIC MARKER;

ADAPTIVE IMMUNITY; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL DIFFERENTIATION; DISEASE COURSE; EPIGENETICS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; SEX CHROMOSOME; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; X CHROMOSOME INACTIVATION; FEMALE; GENETIC EPIGENESIS; GENETIC MARKER; GENETIC PREDISPOSITION; HEREDITY; IMMUNOLOGY; INTRAHEPATIC BILE DUCT; LIVER CIRRHOSIS, BILIARY; MALE; PATHOLOGY; PEDIGREE; PHENOTYPE; RISK FACTOR; SEX DIFFERENCE;

BILE DUCTS, INTRAHEPATIC; EPIGENESIS, GENETIC; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HEREDITY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LIVER CIRRHOSIS, BILIARY; MALE; PEDIGREE; PHENOTYPE; RISK FACTORS; SEX FACTORS;

EID: 84905027623     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1383725     Document Type: Article

References (125)

1. Invernizzi P., Selmi C., Gershwin M. E. Update on primary biliary cirrhosis. Dig Liver Dis: 2010; 42 6 401 408
2. Lleo A., Invernizzi P. Apotopes and innate immune system: novel players in the primary biliary cirrhosis scenario. Dig Liver Dis: 2013; 45 8 630 636
3. Podda M., Selmi C., Lleo A., Moroni L., Invernizzi P. The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. J Autoimmun: 2013; 46 81 87
4. Tsuda M., Zhang W., Yang G. X., et al. Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFβ receptor type II mice. Hepatology: 2013; 57 2 806 816
5. Ando Y., Yang G. X., Tsuda M., et al. The immunobiology of colitis and cholangitis in interleukin-23p19 and interleukin-17A deleted dominant negative form of transforming growth factor beta receptor type II mice. Hepatology: 2012; 56 4 1418 1426
6. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol: 2009; 51 2 237 267
7. Invernizzi P., Battezzati P. M., Crosignani A., et al. Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis. J Hepatol: 2003; 38 4 401 406
8. Invernizzi P., Selmi C., Poli F., et al. Italian PBC Genetic Study Group. Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. Hepatology: 2008; 48 6 1906 1912
9. Donaldson P. T., Baragiotta A., Heneghan M. A., et al. HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: a large-scale study. Hepatology: 2006; 44 3 667 674
10. Invernizzi P. Human leukocyte antigen in primary biliary cirrhosis: an old story now reviving. Hepatology: 2011; 54 2 714 723
11. Hirschfield G. M., Liu X., Xu C., et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med: 2009; 360 24 2544 2555
12. Liu X., Invernizzi P., Lu Y., et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet: 2010; 42 8 658 660
13. Mells G. F., Floyd J. A., Morley K. I., et al. UK PBC Consortium; Wellcome Trust Case Control Consortium 3. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet: 2011; 43 11 1164
14. Nakamura M., Nishida N., Kawashima M., et al. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet: 2012; 91 4 721 728
15. Juran B. D., Hirschfield G. M., Invernizzi P., et al. Italian PBC Genetics Study Group. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Hum Mol Genet: 2012; 21 23 5209 5221
16. Liu J. Z., Almarri M. A., Gaffney D. J., et al. UK Primary Biliary Cirrhosis (PBC) Consortium; Wellcome Trust Case Control Consortium 3. Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis. Nat Genet: 2012; 44 10 1137 1141
17. Kar S. P., Seldin M. F., Chen W., et al. Italian PBC Genetics Study Group. Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. Genes Immun: 2013; 14 3 179 186
18. Carbone M., Lleo A., Sandford R. N., Invernizzi P. Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis. Eur J Immunol: 2014; 44 4 945 954
19. Bach N., Schaffner F. Familial primary biliary cirrhosis. J Hepatol: 1994; 20 6 698 701
20. Brind A. M., Bray G. P., Portmann B. C., Williams R. Prevalence and pattern of familial disease in primary biliary cirrhosis. Gut: 1995; 36 4 615 617
21. Fagan E., Williams R., Cox S. Primary biliary cirrhosis in mother and daughter. BMJ: 1977; 2 6096 1195
22. Floreani A., Naccarato R., Chiaramonte M. Prevalence of familial disease in primary biliary cirrhosis in Italy. J Hepatol: 1997; 26 3 737 738
23. Jaup B. H., Zettergren L. S. Familial occurrence of primary biliary cirrhosis associated with hypergammaglobulinemia in descendants: a family study. Gastroenterology: 1980; 78 3 549 555
24. Jones D. E., Watt F. E., Metcalf J. V., Bassendine M. F., James O. F. Familial primary biliary cirrhosis reassessed: a geographically-based population study. J Hepatol: 1999; 30 3 402 407
25. Lazaridis K. N., Juran B. D., Boe G. M., et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology: 2007; 46 3 785 792
26. Tsuji K., Watanabe Y., Van De Water J., et al. Familial primary biliary cirrhosis in Hiroshima. J Autoimmun: 1999; 13 1 171 178
27. Invernizzi P., Selmi C., Mackay I. R., Podda M., Gershwin M. E. From bases to basis: linking genetics to causation in primary biliary cirrhosis. Clin Gastroenterol Hepatol: 2005; 3 5 401 410
28. Invernizzi P. Role of X chromosome defects in primary biliary cirrhosis. Hepatol Res: 2007; 37 3 03 S384 S388
29. Milkiewicz P., Heathcote J. Primary biliary cirrhosis in a patient with Turner syndrome. Can J Gastroenterol: 2005; 19 10 631 633
30. Invernizzi P., Pasini S., Selmi C., Gershwin M. E., Podda M. Female predominance and X chromosome defects in autoimmune diseases. J Autoimmun: 2009; 33 1 12 16
31. Invernizzi P., Miozzo M., Battezzati P. M., et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet: 2004; 363 9408 533 535
32. Invernizzi P., Miozzo M., Selmi C., et al. X chromosome monosomy: a common mechanism for autoimmune diseases. J Immunol: 2005; 175 1 575 578
33. Invernizzi P., Miozzo M., Oertelt-Prigione S., et al. X monosomy in female systemic lupus erythematosus. Ann N Y Acad Sci: 2007; 1110 84 91
34. Bianchi I., Lleo A., Gershwin M. E., Invernizzi P. The X chromosome and immune associated genes. J Autoimmun: 2012; 38 2-3 J187 J192
35. Lleo A., Oertelt-Prigione S., Bianchi I., et al. Y chromosome loss in male patients with primary biliary cirrhosis. J Autoimmun: 2013; 41 87 91
36. Mitchell M. M., Lleo A., Zammataro L., et al. Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis. Epigenetics: 2011; 6 1 95 102
37. Lleo A., Liao J., Invernizzi P., et al. Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. Hepatology: 2012; 55 1 153 160
38. Hewagama A., Richardson B. The genetics and epigenetics of autoimmune diseases. J Autoimmun: 2009; 33 1 3 11
39. Duerr R. H., Taylor K. D., Brant S. R., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science: 2006; 314 5804 1461 1463
40. Sladek R., Rocheleau G., Rung J., et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature: 2007; 445 7130 881 885
41. Collins F. S., Guyer M. S., Charkravarti A. Variations on a theme: cataloging human DNA sequence variation. Science: 1997; 278 5343 1580 1581
42. Hindorff L. A., Sethupathy P., Junkins H. A., et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A: 2009; 106 23 9362 9367
43. McKay F. C., Hoe E., Parnell G., et al. IL7Rα expression and upregulation by IFNβ in dendritic cell subsets is haplotype-dependent. PLoS ONE: 2013; 8 10 e77508
44. Ouyang W., Oh S. A., Ma Q., Bivona M. R., Zhu J., Li M. O. TGF-β cytokine signaling promotes CD8+ T cell development and low-affinity CD4+ T cell homeostasis by regulation of interleukin-7 receptor α expression. Immunity: 2013; 39 2 335 346
45. Tsuda M., Moritoki Y., Lian Z. X., et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology: 2012; 55 2 512 521
46. Li Q., Verma I. M. NF-kappaB regulation in the immune system. Nat Rev Immunol: 2002; 2 10 725 734
47. Greenwald R. J., Freeman G. J., Sharpe A. H. The B7 family revisited. Annu Rev Immunol: 2005; 23 515 548
48. Scalapino K. J., Daikh D. I. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol Rev: 2008; 223 143 155
49. Dhirapong A., Yang G. X., Nadler S., et al. Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology: 2013; 57 2 708 715
50. Genovese M. C., Becker J. C., Schiff M., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med: 2005; 353 11 1114 1123
51. Kremer J. M., Dougados M., Emery P., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum: 2005; 52 8 2263 2271
52. Abrams J. R., Lebwohl M. G., Guzzo C. A., et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest: 1999; 103 9 1243 1252
53. Zhernakova A., van Diemen C. C., Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet: 2009; 10 1 43 55
54. Kita H., Matsumura S., He X. S., et al. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. J Clin Invest: 2002; 109 9 1231 1240
55. Becher B., Durell B. G., Noelle R. J. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest: 2002; 110 4 493 497
56. Lleo A., Gershwin M. E., Mantovani A., Invernizzi P. Towards common denominators in primary biliary cirrhosis: the role of IL-12. J Hepatol: 2012; 56 3 731 733
57. Yoshida K., Yang G. X., Zhang W., et al. Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. Hepatology: 2009; 50 5 1494 1500
58. Mannon P. J., Fuss I. J., Mayer L., et al. Anti-IL-12 Crohn's Disease Study Group. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med: 2005; 352 12 1276
59. Burakoff R., Barish C. F., Riff D., et al. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis: 2006; 12 7 558 565
60. Leonardi C. L., Kimball A. B., Papp K. A., et al. PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet: 2008; 371 9625 1665 1674
61. Hochdörfer T., Kuhny M., Zorn C. N., et al. Activation of the PI3K pathway increases TLR-induced TNF-α and IL-6 but reduces IL-1β production in mast cells. Cell Signal: 2011; 23 5 866 875
62. Frey R. S., Gao X., Javaid K., Siddiqui S. S., Rahman A., Malik A. B. Phosphatidylinositol 3-kinase gamma signaling through protein kinase Czeta induces NADPH oxidase-mediated oxidant generation and NF-kappaB activation in endothelial cells. J Biol Chem: 2006; 281 23 16128 16138
63. Koyasu S. The role of PI3K in immune cells. Nat Immunol: 2003; 4 4 313 319
64. Varjosalo M., Taipale J. Hedgehog: functions and mechanisms. Genes Dev: 2008; 22 18 2454 2472
65. Ingham P. W., McMahon A. P. Hedgehog signaling in animal development: paradigms and principles. Genes Dev: 2001; 15 23 3059 3087
66. Bhardwaj G., Murdoch B., Wu D., et al. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol: 2001; 2 2 172 180
67. Jung Y., McCall S. J., Li Y. X., Diehl A. M. Bile ductules and stromal cells express hedgehog ligands and/or hedgehog target genes in primary biliary cirrhosis. Hepatology: 2007; 45 5 1091 1096
68. Omenetti A., Popov Y., Jung Y., et al. The hedgehog pathway regulates remodelling responses to biliary obstruction in rats. Gut: 2008; 57 9 1275 1282
69. Omenetti A., Syn W. K., Jung Y., et al. Repair-related activation of hedgehog signaling promotes cholangiocyte chemokine production. Hepatology: 2009; 50 2 518 527
70. Tacke F., Luedde T., Trautwein C. Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol: 2009; 36 1 4 12
71. Locksley R. M., Killeen N., Lenardo M. J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell: 2001; 104 4 487 501
72. Del Villar K., Miller C. A. Down-regulation of DENN/MADD, a TNF receptor binding protein, correlates with neuronal cell death in Alzheimer's disease brain and hippocampal neurons. Proc Natl Acad Sci U S A: 2004; 101 12 4210 4215
73. Sleiman P. M., Flory J., Imielinski M., et al. Variants of DENND1B associated with asthma in children. N Engl J Med: 2012; 366 7 672
74. Kitamura K., Nakamoto Y., Akiyama M., et al. Pathogenic roles of tumor necrosis factor receptor p55-mediated signals in dimethylnitrosamine-induced murine liver fibrosis. Lab Invest: 2002; 82 5 571 583
75. Lleo A., Bowlus C. L., Yang G. X., et al. Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology: 2010; 52 3 987 998
76. Neuman M., Angulo P., Malkiewicz I., et al. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol: 2002; 17 2 196 202
77. Pessach I. M., Notarangelo L. D. X-linked primary immunodeficiencies as a bridge to better understanding X-chromosome related autoimmunity. J Autoimmun: 2009; 33 1 17 24
78. Lleo A., Moroni L., Caliari L., Invernizzi P. Autoimmunity and Turner's syndrome. Autoimmun Rev: 2012; 11 6-7 A538 A543
79. Selmi C., Invernizzi P., Zuin M., Podda M., Seldin M. F., Gershwin M. E. Genes and (auto)immunity in primary biliary cirrhosis. Genes Immun: 2005; 6 7 543 556
80. Selmi C., Invernizzi P., Miozzo M., Podda M., Gershwin M. E. Primary biliary cirrhosis: does X mark the spot? Autoimmun Rev: 2004; 3 7-8 493 499
81. Bogdanos D. P., Smyk D. S., Rigopoulou E. I., et al. Twin studies in autoimmune disease: genetics, gender and environment. J Autoimmun: 2012; 38 2-3 J156 J169
82. Invernizzi P., Alessio M. G., Smyk D. S., et al. Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. BMC Gastroenterol: 2012; 12 92
83. Smyk D. S., Rigopoulou E. I., Lleo A., et al. Immunopathogenesis of primary biliary cirrhosis: an old wives' tale. Immun Ageing: 2011; 8 1 12
84. Smyk D. S., Rigopoulou E. I., Pares A., et al. Sex differences associated with primary biliary cirrhosis. Clin Dev Immunol: 2012; 2012 610504
85. Smyk D. S., Rigopoulou E. I., Pares A., Mytilinaiou M. G., Invernizzi P., Bogdanos D. P. Familial primary biliary cirrhosis: like mother, like daughter? Acta Gastroenterol Belg: 2012; 75 2 203 209
86. Svyryd Y., Hernández-Molina G., Vargas F., Sánchez-Guerrero J., Segovia D. A., Mutchinick O. M. X chromosome monosomy in primary and overlapping autoimmune diseases. Autoimmun Rev: 2012; 11 5 301 304
87. Lleo A., Battezzati P. M., Selmi C., Gershwin M. E., Podda M. Is autoimmunity a matter of sex? Autoimmun Rev: 2008; 7 8 626 630
88. Miozzo M., Selmi C., Gentilin B., et al. Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology: 2007; 46 2 456 462
89. Persani L., Bonomi M., Lleo A., et al. Increased loss of the Y chromosome in peripheral blood cells in male patients with autoimmune thyroiditis. J Autoimmun: 2012; 38 2-3 J193 J196
90. Quintana-Murci L., Krausz C., McElreavey K. The human Y chromosome: function, evolution and disease. Forensic Sci Int: 2001; 118 2-3 169 181
91. Chueh F. Y., Leong K. F., Cronk R. J., Venkitachalam S., Pabich S., Yu C. L. Nuclear localization of pyruvate dehydrogenase complex-E2 (PDC-E2), a mitochondrial enzyme, and its role in signal transducer and activator of transcription 5 (STAT5)-dependent gene transcription. Cell Signal: 2011; 23 7 1170 1178
92. Noelle R. J., Nowak E. C. Cellular sources and immune functions of interleukin-9. Nat Rev Immunol: 2010; 10 10 683 687
93. Merino R., Fossati L., Lacour M., Izui S. Selective autoantibody production by Yaa+ B cells in autoimmune Yaa(+)-Yaa- bone marrow chimeric mice. J Exp Med: 1991; 174 5 1023 1029
94. Subramanian S., Tus K., Li Q. Z., et al. A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci U S A: 2006; 103 26 9970 9975
95. Fairhurst A. M., Hwang S. H., Wang A., et al. Yaa autoimmune phenotypes are conferred by overexpression of TLR7. Eur J Immunol: 2008; 38 7 1971 1978
96. Santiago-Raber M. L., Kikuchi S., Borel P., et al. Evidence for genes in addition to Tlr7 in the Yaa translocation linked with acceleration of systemic lupus erythematosus. J Immunol: 2008; 181 2 1556 1562
97. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet: 2011; 12 12 861 874
98. Katoh H., Zheng P., Liu Y. FOXP3: genetic and epigenetic implications for autoimmunity. J Autoimmun: 2013; 41 72 78
99. Lu Q. The critical importance of epigenetics in autoimmunity. J Autoimmun: 2013; 41 1 5
100. Wang Q., Selmi C., Zhou X., et al. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. J Autoimmun: 2013; 41 140 145
101. Selmi C., Mayo M. J., Bach N., et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology: 2004; 127 2 485 492
102. Gay S., Wilson A. G. The emerging role of epigenetics in rheumatic diseases. Rheumatology (Oxford): 2014; 53 3 406 414
103. Pillai S. Rethinking mechanisms of autoimmune pathogenesis. J Autoimmun: 2013; 45 97 103
104. Costenbader K. H., Gay S., Alarcón-Riquelme M. E., Iaccarino L., Doria A. Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev: 2012; 11 8 604 609
105. Selmi C., Cavaciocchi F., Lleo A., et al. Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosis. Front Immunol: 2014; 5 128
106. Carrel L., Willard H. F. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature: 2005; 434 7031 400 404
107. Ozbalkan Z., BagiŚlar S., Kiraz S., et al. Skewed X chromosome inactivation in blood cells of women with scleroderma. Arthritis Rheum: 2005; 52 5 1564 1570
108. Brix T. H., Knudsen G. P., Kristiansen M., Kyvik K. O., Orstavik K. H., Hegedüs L. High frequency of skewed X-chromosome inactivation in females with autoimmune thyroid disease: a possible explanation for the female predisposition to thyroid autoimmunity. J Clin Endocrinol Metab: 2005; 90 11 5949 5953
109. Uz E., Loubiere L. S., Gadi V. K., et al. Skewed X-chromosome inactivation in scleroderma. Clin Rev Allergy Immunol: 2008; 34 03 352 355
110. Ozcelik T. X chromosome inactivation and female predisposition to autoimmunity. Clin Rev Allergy Immunol: 2008; 34 03 348 351
111. Higuchi M., Horiuchi T., Kojima T., et al. Analysis of CD40 ligand gene mutations in patients with primary biliary cirrhosis. Scand J Clin Lab Invest: 1998; 58 5 429 432
112. Zheng Y., Rudensky A. Y. Foxp3 in control of the regulatory T cell lineage. Nat Immunol: 2007; 8 5 457 462
113. Padgett K. A., Lan R. Y., Leung P. C., et al. Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun: 2009; 32 3-4 246 253
114. Qin B., Huang F., Liang Y., Yang Z., Zhong R. Analysis of altered microRNA expression profiles in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. J Gastroenterol Hepatol: 2013; 28 3 543 550
115. Banales J. M., Sáez E., Uriz M., et al. Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology: 2012; 56 2 687 697
116. Ando Y., Yang G. X., Kenny T. P., et al. Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-β receptor type II mouse. J Autoimmun: 2013; 41 111 119
117. Ninomiya M., Kondo Y., Funayama R., et al. Distinct microRNAs expression profile in primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers. PLoS ONE: 2013; 8 6 e66086
118. Qian C., Chen S. X., Ren C. L., Zhong R. Q., Deng A. M., Qin Q. [Abnormal expression of miR-let-7b in primary biliary cirrhosis and its clinical significance]. Zhonghua Gan Zang Bing Za Zhi: 2013; 21 7 533 536
119. Hirschfield G. M., Liu X., Han Y., et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet: 2010; 42 8 655 657
120. Liu J. Z., Hov J. R., Folseraas T., et al. UK-PSCSC Consortium; International IBD Genetics Consortium; International PSC Study Group. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet: 2013; 45 6 670 675
121. TaŚ S., Avci O. Rapid clearance of psoriatic skin lesions induced by topical cyclopamine. A preliminary proof of concept study. Dermatology: 2004; 209 2 126 131
122. Feldmann M., Maini R. N. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med: 2003; 9 10 1245 1250
123. Braun J., Davis J., Dougados M., Sieper J., van der Linden S., van der Heijde D. ASAS Working Group First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis: 2006; 65 3 316 320
124. Gisondi P., Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev: 2007; 6 8 515 519
125. Rutgeerts P., Vermeire S., Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology: 2009; 136 4 1182 1197